bioRxiv Science⌕ Search

Biology subjects

Justine, M.

Publications and source records attributed to Justine, M..

2 recordsLinked to original sources

In vivo de-amplification of a multi-resistance pseudo-compound transposon in Escherichia coli

The rapid expansion of antimicrobial resistance (AMR) among Gram-negative pathogens presents a major clinical challenge, particularly in vulnerable populations such as infants. The dissemination of resistance is often mediated by mobile genetic elements (MGEs) that can mobilise antimicrobial resistance genes (ARGs) both within and between genomes. The insertion sequence (IS) IS26, is a MGE with the ability to replicate itself and associated ARGs, create translocatable units (TU), and produce tandem arrays of ARGs. Here we present the 18-week in vivo evolution of a community-acquired multi-drug resistant (MDR) Escherichia coli colonising an infant gut, characterised by a de-amplification of an IS26-mediated tandem array of ARGs. The hybrid-assembled ancestral and descendant strain genomes show an evolutionary rate of 10.22 SNPs per genome per year. Independent analysis of the hybrid genome assembly, and of Oxford Nanopore Technologies (ONT) and Illumina read-mapping support the existence of at least five copies of a TU (Tn3-like(tnpA)-tetR-tetA-yedA-{Delta}Tn1721(tnpA) -IS26-aac(6)-Ib-cr-blaOXA-1-{Delta}catB3-IS26) in the ancestor and only one in the descendant. Despite de-amplification, no change in fitness (p = 0.275) and piperacillin-tazobactam susceptibility (TZP) was observed. In contrast, gentamicin susceptibility increased, in the absence of known associated mutations. This study provides insight into IS26-mobility dynamics in vivo and their implications for AMR, within the rapidly changing environment of the neonatal gut.

microbiology↗

Metabolic reprogramming of the infant gut by bifidobacteria-based probiotics drives exclusion of antibiotic-resistant pathobionts

Early-life probiotics have emerged as a promising strategy to combat the global emergency of antimicrobial resistance by enhancing gut resilience in infants. However, how exactly probiotic bacteria affect resistant opportunistic pathogens, i.e., pathobionts, remains nascent. We investigated effects of probiotic supplementation in 152 full-term, healthy Tanzanian infants, a sub-cohort of the ProRIDE trial (NCT04172012). Administration of oral probiotics during the first 4 weeks of life led to enhanced gut colonization by the probiotic Bifidobacterium species while suppressing pathobionts such as extended-spectrum {beta}-lactamase-producing Enterobacterales (ESBL-E). Integration of metagenomics with metabolomics revealed that probiotics decreased resistome load and mobilome richness at 6 weeks, with concurrent shifts in metabolome. Specifically, the intervention increased fecal lactate and pyruvate and reduced cross-feeding pathways leading to propionate and butyrate, which partly explained the reduced ESBL-E carriage. Our findings provide mechanistic insights into how probiotic-driven Bifidobacterium colonization modulates infant gut ecosystem to attenuate antimicrobial resistance in infancy.

microbiology↗